Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Trial Profile

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary) ; Cisplatin
  • Indications Stomatitis
  • Focus Therapeutic Use
  • Acronyms PREVLAR
  • Sponsors EpicentRx
  • Most Recent Events

    • 01 Jul 2023 Results assessing the safety and efficacy of RRx-001 in patients receiving head and neck chemoradiotherapy, published in the International Journal of Radiation Oncology, Biology, Physics.
    • 02 Jun 2023 Results presented in an EpicentRx Media Release.
    • 02 Jun 2023 According to an EpicentRx media release, based on results from this trial the U.S. Food and Drug Administration (FDA) granted Fast Track designation, which expedites the development and review process for RRx-001.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top